Erectile dysfunction and statin treatment in high cardiovascular risk patients

International Journal of Clinical Practice

Volumn 60, Issue 2, 2006, Pages 141-145

  Solomon, H ^a   Samarasinghe, Y P ^b   Feher, M D ^b   Man, J ^a   Rivas Toro, H ^b   Lumb, P J ^a   Wierzbicki, Anthony S ^a   Jackson, G ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Angiotensin 2; Cardiovascular risk; Erectile dysfunction; Impotence; Statin (HMG CoA reductase inhibitor)

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; ORAL ANTIDIABETIC AGENT; WARFARIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; ENDOTHELIUM LESION; ERECTILE DYSFUNCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LIPOPHILICITY; MAJOR CLINICAL STUDY; MALE; PENIS ERECTION; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM;

ADULT; ATHEROSCLEROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMPOTENCE, VASCULOGENIC; MALE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 33646710811     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.00793.x     Document Type: Article

References (23)

1. Bortolotti A, Parazzini F, Colli E et al. The epidemiology of erectile dysfunction and its risk factors. Int J Androl 1997; 20: 323-34.
2. Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: Endothelial dysfunction is the common denominator. Heart 2003; 89: 251-3.
3. Bruckert E, Giral P, Heshmati HM et al. Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J Clin Pharm Ther 1996; 21: 89-94.
4. Lewis RW. Epidemiology of erectile dysfunction. Urol Clin North Am 2001; 28: 209-16, vii.
5. Modebe O. Erectile failure among medical clinic patients. Afr J Med Med Sci 1990; 19: 259-64.
6. Maas R, Schwedhelm E, Albsmeier J et al. The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function. Vasc Med 2002; 7: 213-25.
7. Rosen RC, Cappelleri JC, Smith MD et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319-26.
8. Solomon H, Man JW, Wierzbicki AS et al. Relation of erectile dysfunction to angiographic coronary artery disease. Am J Cardiol 2003; 91: 230-1.
9. Solomon H, Man J, Wierzbicki AS et al. Erectile dysfunction: cardiovascular risk and the role of the cardiologist. Int J Clin Pract 2003; 57: 96-9.
10. Jackson G. Erectile dysfunction and cardiovascular disease. Int J Clin Pract 1999; 53: 363-8.
11. Feldman HA, Johannes CB, Derby CA et al. Erectile dysfunction and coronary risk factors: Prospective results from the Massachusetts male aging study. Prev Med 2000; 30: 328-38.
12. Jackson G, Simvastatin and Impotence. Br Med J 1997; 351: 31.
13. Boyd IW. Comment: HMG-CoA reductase inhibitor-induced impotence. Ann Pharmacother 1996; 30: 1199.
14. Saltzman EA, Guay AT, Jacobson J. Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: A clinical observation. J Urol 2004; 172: 255-8.
15. Keene LC, Davies PH. Drug-related erectile dysfunction. Adverse Drug React Toxicol Rev 1999; 18: 5-24.
16. Toda N. Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther 2003; 100: 215-34.
17. Cruickshank JM. What does the future hold for ACE inhibitors? J Hum Hypertens 1991; 5 (Suppl. 2): 41-7.
18. Blumentals WA, Brown RR, Gomez-Caminero A. Antihypertensive treatment and erectile dysfunction in a cohort of type II diabetes patients. Int J Impot Res 2003; 15: 314-7.
19. Fogari R, Zoppi A. Effect of antihypertensive agents on quality of life in the elderly. Drugs Aging 2004; 21: 377-93.
20. Dusing R. Effect of the angiotensin ii antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl 2003; (Suppl. 2) 29-34.
21. Llisterri JL, Lozano Vidal JV, Aznar VJ et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 2001; 321: 336-41.
22. Jensen J, Lendorf A, Stimpel H et al. The prevalence and etiology of impotence in 101 male hypertensive outpatients. Am J Hypertens 1999; 12: 271-5.
23. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: Early safety and efficacy experience. Eur Heart J 1999; 20: 725-41.